Biogen has announced new data behind the Alzheimer’s drug aducanumab suggests it was working on early stage patients. Jeff Borghoff was a participant for…
SAN DIEGO — I’m not a doctor. I’m not a scientist. I barely made it through my math and science classes in college. Actually,…
I wasn’t yet fully awake this morning when I started poking through my Facebook feed and saw the head-spinning news that Biogen had reversed…
In a dizzying reversal, Biogen announced today that it would seek approval from the U.S. Food and Drug Administration (FDA) to begin marketing its…
Clinical trial participants, researchers and investors were reeling on Thursday after Biogen and Eisai, its Japanese pharmaceutical partner, announced that they would be halting two…
Sign up for a weekly digest of the latest research on Alzheimer’s and brain health.
Follow us